Understanding type 17 immune responses in AS and developing therapies to target these
Our group is currently studying in detail the phenotype and function of type 17 responses in AS.
The type 17/23 axis is now an important target for therapeutic drug and antibody development. We are also working on small molecule inhibitors of ERAP1, of the transcription factor ROR gamma T and of the (epigenetic) bromodomain readers and transcriptional co-activators CBP and p300. Our data show that all can inhibit Type17 responses in vitro.